BridgeBio Pharma (NASDAQ:BBIO) reported quarterly losses of $(0.78) per share which missed the analyst consensus estimate of $(0.59) by 32.2 percent. This is a 17.89 percent increase over losses of $(0.95) per share from the same period last year. The company reported quarterly sales of $243.676 million which beat the analyst consensus estimate of $218.743 million by 11.40 percent. This is a 120.39 percent increase over sales of $110.565 million the same period last year.